Evidence map›Paper›PMID 25955717›Full record

ArticlePLoS pathogens2015

Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2/IRAK1/NFκB Signaling Pathway.

Igor Landais, Chantel Pelton, Daniel Streblow, Victor DeFilippis, Shannon McWeeney, Jay A Nelson

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Cancers · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Viral miRNA regulation of host gene expression.Seminars in cell & developmental biology · 2023
    Review
  18. Article
  19. Review
  20. Deletion of the non-adjacent genesFrontiers in immunology · 2023
    Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Igor LandaisVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Chantel PeltonVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Daniel StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Victor DeFilippisVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Shannon McWeeneyDivision of Biostatistics, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon, United States of America.
Jay A NelsonVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
Oregon Health & Science University · US

Funding

MOLECULAR ASPECTS OF CYTOMEGALOVIRUS LATENCYR01AI021640 · NIAID · UNIVERSITY OF GUELPH · PI Meaghan H Hancock · 1985 to 2026
$8.1M
Molecular Aspects of Cytomegalovirus LatencyR37AI021640 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANCOCK, MEAGHAN H · 2018 to 2024
$4.0M
NIAID NIH HHS AI21640NIAID NIH HHS R01 AI021640NIAID NIH HHS R37 AI021640
6 · The paper itself

Abstract

Human Cytomegalovirus (HCMV) encodes multiple microRNAs (miRNAs) whose functions are just beginning to be uncovered. Using in silico approaches, we identified the Toll-Like Receptor (TLR) innate immunity pathway as a possible target of HCMV miRNAs. Luciferase reporter assay screens further identified TLR2 as a target of HCMV miR-UL112-3p. TLR2 plays a major role in innate immune response by detecting both bacterial and viral ligands, including HCMV envelope proteins gB and gH. TLR2 activates a variety of signal transduction routes including the NFκB pathway. Furthermore, TLR2 plays an important role in controlling CMV infection both in humans and in mice. Immunoblot analysis of cells transfected with a miR-UL112-3p mimic revealed that endogenous TLR2 is down-regulated by miR-UL112-3p with similar efficiency as a TLR2-targeting siRNA (siTLR2). We next found that TLR2 protein level decreases at late times during HCMV infection and correlates with miR-UL112-3p accumulation in fibroblasts and monocytic THP1 cells. Confirming direct miR-UL112-3p targeting, down-regulation of endogenous TLR2 was not observed in cells infected with HCMV mutants deficient in miR-UL112-3p expression, but transfection of miR-UL112-3p in these cells restored TLR2 down-regulation. Using a NFκB reporter cell line, we found that miR-UL112-3p transfection significantly inhibited NFκB-dependent luciferase activity with similar efficiency as siTLR2. Consistent with this observation, miR-UL112-3p transfection significantly reduced the expression of multiple cytokines (IL-1β, IL-6 and IL-8) upon stimulation with a TLR2 agonist. Finally, miR-UL112-3p transfection significantly inhibited the TLR2-induced post-translational activation of IRAK1, a kinase located in the upstream section of the TLR2/NFκB signaling axis. To our knowledge, this is the first identified mechanism of TLR2 modulation by HCMV and is the first report of functional targeting of TLR2 by a viral miRNA. These results provide a novel mechanism through which a HCMV miRNA regulates the innate immune response by down-regulating TLR-2 expression.

Indexed as

RNA InterferenceSignal Transduction3' Untranslated RegionsCells, CulturedCytomegalovirusFibroblastsGenes, ReporterHEK293 CellsHumansImmunity, InnateInterleukin-1 Receptor-Associated KinasesLigandsMicroRNAsMonocytesMutationNF-kappa B3' Untranslated RegionsInterleukin-1 Receptor-Associated KinasesIRAK1 protein, humanLigandsMicroRNAsmicroRNA-UL112, human cytomegalovirusNF-kappa BRecombinant ProteinsRNA, Small InterferingRNA, ViralTLR2 protein, humanToll-Like Receptor 2

Identifiers

PMID25955717
PMCPMC4425655
OpenAlexW407529895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.